- Home
- TPST vs LGVN Comparison
TPST vs LGVN Comparison
Compare TPST & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPST | LGVN |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 17.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TPST | LGVN |
|---|---|---|
| Price | $3.11 | $0.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $12.50 | $6.50 |
| AVG Volume (30 Days) | 240.3K | ★ 397.5K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,437,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.00 | $0.58 |
| 52 Week High | $13.65 | $2.24 |
Technical Indicators
Market Signals| Indicator | TPST | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 25.89 | 39.34 |
| Support Level | $3.04 | $0.58 |
| Resistance Level | $3.23 | $0.65 |
| Average True Range (ATR) | 0.26 | 0.04 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 9.02 | 26.77 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.